The FDA has approved a groundbreaking new antipsychotic drug for schizophrenia, the first of its kind in decades, providing hope for the 1.8 percent of the U.S. adult population affected by this mental health condition. (source).
Bristol Myers Squibb (BMS), the company behind the drug, hailed the FDA approval as a “landmark” moment that could revolutionize schizophrenia treatment. (source)
The newly approved drug, Cobenfy, takes a unique approach by targeting cholinergic receptors instead of dopamine receptors, aiming to reduce common side effects while treating symptoms. (source)
Advocates believe Cobenfy could improve patients’ ability to engage in daily life and social activities, potentially enhancing their quality of life.
The cost of Cobenfy is expected to be comparable to other antipsychotic medications on the market, with a wholesale price of $1,850 per month. (source)
This approval showcases the success of market-driven medication development, contrasting with the challenges faced by government-funded research efforts in the field of mental health. (source)
Despite significant investments in research, schizophrenia researchers acknowledge the limited progress in developing effective treatments, highlighting the need for innovative approaches like Cobenfy.
